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A novel paradigm in tumor biology suggests that
cancer growth is driven by stem-like cells within
a tumor, called tumor-initiating cells (TICs) or cancer
stem cells (CSCs). Here we describe the identifica-
tion and characterization of such cells from hepato-
cellular carcinoma (HCC) using the marker CD133.
CD133 accounts for approximately 1.3%–13.6% of
the cells in the bulk tumor of human primary HCC
samples. When compared with their CD133 coun-
terparts, CD133+ cells not only possess the preferen-
tial ability to form undifferentiated tumor spheroids
in vitro but also express an enhanced level of stem
cell-associated genes, have a greater ability to form
tumors when implanted orthotopically in immunode-
ficient mice, and can be serially passaged into
secondary animal recipients. Xenografts resemble
the original human tumor and maintain a similar
percentage of tumorigenic CD133+ cells. Quantita-
tive PCR analysis of 41 separate HCC tissue speci-
mens with follow-up data found that CD133+ tumor
cells were frequently detected at low quantities in
HCC, and their presence was also associated with
worse overall survival and higher recurrence rates.
Subsequent differential microRNA expression
profiling of CD133+ and CD133 cells from human
HCC clinical specimens and cell lines identified an
overexpression of miR-130b in CD133+ TICs. Func-
tional studies on miR-130b lentiviral-transduced
CD133 cells demonstrated superior resistance to
chemotherapeutic agents, enhanced tumorigenicity
in vivo, and a greater potential for self renewal.
Conversely, antagonizing miR-130b in CD133+
TICs yielded an opposing effect. The increased694 Cell Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier IncmiR-130b paralleled the reduced TP53INP1, a known
miR-130b target. Silencing TP53INP1 in CD133 cells
enhanced both self renewal and tumorigenicity
in vivo. Collectively, miR-130b regulates CD133+ liver
TICs, in part, via silencing TP53INP1.
INTRODUCTION
Human epithelial cell-derived cancers are highly heterogeneous
in their morphologies, clinical behaviors, and molecular profiles.
The tumor-initiating cell (TIC) or cancer stem cell (CSC) con-
cept suggests that tumors are organized in a hierarchy of mixed
tumor cells and that sitting at the apex is a subset of cancer cells
that are biologically distinct from the others and bear stem cell-
like features, which are indispensable for a tumor. These TICs
possess both self renewal and differentiation capabilities and
are believed to give rise to tumor heterogeneity (Visvader and Lin-
deman, 2008; Jordan et al., 2006; Pardal et al., 2003). Thus, TIC
eradication may be critical to achieving stable remission of, and
evencuring, aggressivemalignancies. Todate, theperpetuations
of many cancer types, including leukemia, breast cancer, brain
cancer, prostate cancer, colon cancer, and hepatocellular carci-
noma (HCC) have been suggested to stem from TICs.
HCC ranks as the fifth most prevalent cancer worldwide,
affecting 1 million individuals annually (Jemal et al., 2009).
Surgical resection and liver transplantation are available for
early-stage HCC, but because most patients are diagnosed at
advanced stages, only 25% of patients with this cancer are
amenable to surgery. Chemotherapy is one of the main treat-
ments given to the remaining patients with inoperable HCC
and is also administered as a pre-/postsurgical adjuvant therapy,
yet the overall response rate to this treatment is low due to the
highly chemotherapy-resistant nature of the disease (Aravalli
et al., 2008). Therefore, understanding the mechanism under-
lying hepatocarcinogenesis is essential for managing HCC.
Recently, we have identified a TIC population from HCC cells
and xenograft tumors that is marked by a CD133 surface.
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renew; differentiate into non-hepatocyte-like, angiomyogenic-
like lineages; initiate tumors in vivo and resist standard chemo-
therapy via the Akt/PKB and Bcl-2 pathways (Ma et al., 2007,
2008). Our findings also correspond with reports by other
research groups (Suetsugu et al., 2006; Yin et al., 2007; Zhu
et al., 2010; Song et al., 2008), thus demonstrating the promi-
nence of CD133 as a marker for TICs in HCC cell lines.
MicroRNAs (miRNAs) are an abundant class of small, noncod-
ing RNAs that negatively regulate gene expression at the post-
transcriptional level by inhibiting ribosome function, decapping
the 50cap structure, deadenylating the poly(A) tail, and degrading
the target mRNA (He and Hannon, 2004; Filipowicz et al., 2008).
miRNAs can regulate and control a variety of biological
processes including developmental timing, signal transduction,
stem cell self renewal, and differentiation (Gangaraju and Lin,
2009; Croce and Calin, 2005; Inui et al., 2010). One of the
best-studied miRNAs, let-7 in C. elegans, was initially identified
in mutants with defects in developmental timing (Reinhart
et al., 2000). The loss of dicer1, an important endonuclease for
the synthesis of mature miRNAs, also induces embryonic
lethality and depletion of stem cells (Bernstein et al., 2003; Hat-
field et al., 2005). In addition, tissue-specific deletion of dicer
affects the self renewal of embryonic stem cells, the develop-
ment of B lymphocyte lineage cells, and tissue morphogenesis
(Chen et al., 2008; Davis et al., 2008; Koralov et al., 2008). The
deletion of DGCR8, another key enzyme for miRNA processing,
alters the silencing of self-renewal genes in embryonic stem cells
(Wang et al., 2007). Moreover, a distinct miRNA subset is specif-
ically expressed in pluripotent embryonic stem cells but not in
adult tissues (Suh et al., 2004).
In addition to regulating cell-fate decisions, somemiRNAs can
also function as tumor promoters or suppressors, regulating the
maintenance and progression of cancers and TICs (DeSano and
Xu, 2009; Esquela-Kerscher and Slack, 2006). The expression of
let-7 prevents tumor sphere formation in breast cancer cell lines
and inhibits tumorigenicity in an in vivo xenograft tumor assay
(Yu et al., 2007). Elevated miR-181 family members were identi-
fied as critical players in regulating EpCAM+ hepatic TICs
(Ji et al., 2009), and the downregulation of miR-200 family
miRNAs suggests that normal stem cells and breast cancer
stem cells share common molecular mechanisms that regulate
stem cell functions, such as self renewal, proliferation, and the
epithelial-mesenchymal transition (Shimono et al., 2009). Finally,
miRNA expression profiles have been correlated with the tumor
stage, progression, and prognosis of cancer patients (Jiang
et al., 2008; Ura et al., 2009; Calin et al., 2005; Iorio et al.,
2005). These findings demonstrate that miRNAs are critical regu-
lators of self renewal, differentiation, and carcinogenesis.
To date, CD133 has only been used to identify liver TICs in cell-
line-based models. The characterization of this specific popula-
tion of cells is also very limited. In this study, we first validated
CD133 as a marker for liver TICs in freshly resected HCC clinical
specimens and identified a prognostic role of CD133 in HCC.
Subsequently, we elucidated the underlying molecular mecha-
nism by which this specific population of cells mediates tumor
formation and growth by a systematic comparison of the miRNA
profiles in CD133+ liver TICs and their differentiated progeny. Our
findings suggest that HCC maintenance and growth is dictated,Celat least in part, by a CD133+-expressing subpopulation and that
miR-130b regulates the growth and self renewal of CD133+ liver
TICs via the direct targeting of TP53INP1.
RESULTS
Identification of CD133+ as Liver TICs in Human HCC
Clinical Specimens
Previous work from our laboratory identified a TIC population
marked by the CD133 surface phenotype in HCC xenograft
tumors and cell lines. CD133+ cells were found capable of exten-
sive proliferation, exhibited an increased potential to self renew
and differentiate, expressed stem cell-associated markers and
were maintained at a low frequency in the bulk of the tumor
mass (Ma et al., 2007). CD133+ cells also contribute to HCC che-
moresistance through Akt/PKB and Bcl-2 pathway activations
(Ma et al., 2008). The identification and characterization of
a CD133+ TIC population in HCC xenograft tumors and cell lines
suggested that CD133 may also represent a TIC marker in
primary human HCC specimens. Therefore, as a first step, we
examined the expression of CD133 in fresh tissue samples
derived from patients with HCC using both flow cytometry and
immunohistochemistry (IHC). In total, 35 individual patients
were analyzed. Flow cytometry demonstrated the presence of
a rare CD133 population in HCC specimens, with expression
ranging from 1.3% to 13.6% (Figure 1A). A potential contamina-
tion of the CD133+ cell population by hematopoietic and endo-
thelial progenitors was excluded by flow cytometry using CD45
and CD31, respectively. CD133+ cells were negative for the pan-
hematopoietic marker CD45, and less than 1.3% of the CD133+
subpopulation was putative CD31+ endothelial progenitors (Fig-
ure 2A). Consistently, histological analysis revealed that similar
percentages of CD133+ cells were localized in the bulk tumor
(Figure 1B). All HCC samples reproducibly demonstrated the
presence of only a rare CD133+ population, while, in contrast,
CD133 expression in nontumor (NT) liver tissues was almost
nonexistent (Figures 1A and 1B). Due to the short follow-up
periodafter the fresh clinical specimenswerecollected, theasso-
ciation between CD133 expression and disease-free survival or
overall survival could not be calculated. However, quantitative
real-time PCR (qPCR) analysis of 41 HCC tissue specimens
that we had collected earlier and for which we have follow-up
data showed that increased CD133 expression in HCC not only
correlated with advanced disease stage but also was associated
with higher recurrence rates and worse overall survival.
Increased CD133 expression in HCC was more associated with
higher tumor stages (T stages III or IV) than with lower tumor
stages (T stages I or II) (c2 test, p = 0.008; Figure 1C and Table
S1). Furthermore, an association study showed the CD133 DCt
value to be inversely correlated with tumor stage in these 41
HCC patients (n = 38, Pearson correlation, r = 0.428, c2 test,
p = 0.007). In a Kaplan-Meier survival analysis, patients with
CD133+ primary tumors displayed worse disease-free survival
(estimated mean = 13.75 months) when compared to those
patients with CD133-/low primary tumors (estimated mean =
61.49 months) (log-rank test, p = 0.001; Figure 1D). In addition,
CD133 expression was also associated with long-term overall
survival. PatientswithCD133+primary tumors hadameanoverall
survival of 27.11 months, as compared with 78.51 months forl Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier Inc. 695
Figure 1. CD133 Expression in HCC Clinical Specimens Is Associated with Advanced Tumor Stage and Poor Prognosis
(A–D) Single cells digested from freshly resectedNT or HCC tissue samples or their corresponding paraffin-embedded formalin-fixed tissue sections were stained
for CD133 and analyzed by either (A) flow cytometry or (B) IHC. Tissue sections were counterstained with H&E. IHC images were taken at 2003magnification. In
total, 35 individual patients were analyzed. qPCR analysis for CD133 expression in 41 HCC tissue specimens found that elevated CD133 expression was asso-
ciated with (C) higher recurrence rates (log-rank test, p = 0.001) and (D) worse overall survival (log-rank test, p < 0.001). The disease-free survival and overall
survival rates significantly decreased in HCC patients with high CD133 expression (orange line; n = 20) compared with HCC patients with low CD133 expression
(blue line; n = 20). See also Tables S1 and S2.
Cell Stem Cell
miR-130b Regulates CD133+ Liver TICs via TP53INP1patients with CD133/low primary tumors (log-rank test,
p < 0.001). Univariate Cox regression analysis also identified
that the tumor stage was significantly associated with disease-
free survival and that the CD133 expression was correlated
with both disease-free and overall survival (Table S2). CD133
expression was, however, not significantly associated with age,
gender, a-fetoprotein (AFP) levels, or tumor size (Table S1).
Next, we evaluated the tumorigenic potential and stem cell-
like properties of isolated CD133+ TICs from freshly resected
HCC. Preliminary data demonstrated that following tumor disso-
ciation into single cells, cells must be at least 70% viable in order
for experiments like in vivo tumorigenicity assays and in vitro
spheroid formation assays to be successful. Among the 83
matched NT and HCC specimens collected, cells isolated from
only one-fourth (n = 21) of the tumor specimens showed >70%
cell viability. Thus, only these 21 samples were used for further
downstream studies, following initial screening for CD133
expression by flow cytometry (n = 35). Following the removal of
dead cells, CD133+ TICswere isolated bymagnetic bead sorting,
which resulted in a considerable enrichment of CD133+ cells
(purity 82%–92%) and, more importantly, a higher negative696 Cell Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier Incselection (purity >98%)ofCD133cells. Again, potential contam-
ination of the CD133+ cell population by hematopoietic and
endothelial progenitors was excluded by flow cytometry using
CD45 and CD31, respectively (Figure 2A; bottom).
Following sorting, we investigated the ability of tumor-derived
CD133+ and CD133 cells to orthotopically engraft and give rise
to tumors in SCID/Beige mice. As many as 5 3 105 patient-
derived CD133 HCC cells resuspended in Matrigel were
needed to initiate occasional tumor formation, while, in contrast,
as few as 2 3 104 CD133+ cells resuspended in Matrigel gener-
ated visible tumors 8 weeks postinjection (Figure 2B and
Table S3; data representative of eight tumors tested). These
data indicate that cells capable of initiating HCC are highly en-
riched within a CD133+ cell population. Additionally, histological
analysis revealed that tumor xenografts derived from CD133+
cells consistently reproduced the primary tumor at the histolog-
ical level (data not shown). To investigate whether CD133+ HCC
cells display long-term tumorigenic potential, we evaluated their
ability to generate tumors in serial transplantations. Sorted
CD133+ and CD133 cells from primary tumor xenografts were
transplanted into secondary mouse recipients. Only CD133+.
Figure 2. Tumorigenic and Stem Cell-like Potential of CD133+ Cells in Patient-Derived HCC Samples
(A) A flow cytometry dot plot shows the distribution of CD133+ cells in unsorted and sorted freshly resected humanHCC specimens. Purity for the positive fraction
ranged from 82%–92%, while the negative fraction achieved greater than 98% purity. Flow cytometry for CD31 and CD45 was performed to detect potential
contamination of isolated cells with endothelial or hematopoietic progenitors. Staining revealed no or very low expression of these cell types in the CD133+
TIC population.
(B) CD133+ TICs isolated from freshly isolated tumors, but not CD133 cells, were capable of inducing tumor formation when orthotopically implanted into the
liver of SCID/Beige mice. See also Table S3. H&E staining of tumors injected with CD133+ TICs revealed malignant cells. Serial transplantation of xenografted
tumors in secondary animal recipients showed enhanced engraftment ability, as demonstrated by the increased number of tumor-bearing mice.
(C) CD133+ TICs were able to generate an increased number of primary and serially passaged spheroids as compared with CD133 cells in freshly isolated
tumors.
(D–F) A flow cytometry histogram analysis shows the enrichment of CD133 expression in mechanically dissociated CD133+ spheroids (purple; ‘‘spheroid’’) as
compared to the differentiated adherent counterpart (dotted green; ‘‘differentiated’’). qPCR analysis was performed for stem cell-associated and multiple-
drug-resistant transporter genes in (E) mechanically dissociated cancer spheroids (‘‘S’’) versus primary adherent HCC cells (‘‘D’’) and (F) CD133+ TICs versus
CD133 cells isolated from freshly resected tumors. Differentiated adherent cells and CD133 were defined as 1 (calibrator), and the relative expression of
each gene was expressed as the fold difference over this baseline. b-actin was used as an internal control.
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better, as evident by the number of tumor-bearing mice (83%
in secondary xenografts versus 65% in primary xenografts),
and they grew more rapidly than those tumors in the primary
xenografts (Figure 2B). Tumor morphologies were indistinguish-
able from either tumors generated from primary animal recipi-
ents or original tumors. Thus, the CD133+ cell population
resident in the HCC tumor mass could generate serial xeno-
grafts, suggesting an in vivo self-renewing capacity.CelNext, we examined the ability of CD133+ TICs and CD133
cells to grow as spheroids in nonadherent, serum-free, growth
factor-supplemented conditions that favor the proliferation of
undifferentiated cells. Within 3 weeks of culture, we obtained
HCC spheres of growing undifferentiated CD133+ cells.
CD133 tumor cells invariably died in such serum-free condi-
tions (Figure 2C; data representative of seven tumors tested).
More importantly, single cells obtained from these CD133+
dissociated spheres could be clonally expanded in subsequentl Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier Inc. 697
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When CD133+ cells were grown as HCC spheres, these cells re-
mained CD133+. To determine the differentiation potential of
these CD133+ cells, tumor spheres were cultivated without
EGF and FGF2 in the presence of 10% serum. After several
days of culture, the spheres differentiated, attached onto the
flasks, and grew as adherent cells. As compared with undifferen-
tiated spheres, adherent counterparts expressed less CD133
expression following induced in vitro differentiation (Figure 2D;
data representative of seven tumors tested). The ability of
CD133+ cells to form spheres and be serially propagated
suggests an in vitro self-renewing capacity. Similarly, the propor-
tions of stem cell-associated genes, including Bmi-1, Notch 1,
Sox2, Oct-4, nanog, b-catenin, Smo, and nestin, and multidrug
resistance transporters ABCG2 and ABCB1 were reduced
following in vitro differentiation of CD133+ TIC spheres (Fig-
ure 2E; data representative of three tumors tested). In addition,
patient-derived CD133+ TICs also expressed an enhanced level
of stem cell-associated genes, including nanog, Oct-4, ABCB1,
and Sox2, when compared with their CD133 tumor counter-
parts (Figure 2F; data representative of three tumors tested).
Collectively, these data demonstrate the existence of a TIC pop-
ulation in HCC marked by a CD133 surface phenotype and
bearing cancer and stem cell-like features including the ability
to self renew, differentiate, and initiate tumors in vivo.
miRNA Profiling of CD133+ TICs and CD133– Cell
Counterparts
Following the identification of CD133+ liver TICs, we furthered
our study to characterize the underlying mechanism that drives
this population of cells and their role in tumor progression.
miRNAs are recognized as important regulators of posttranscrip-
tional gene expression, regulating both cellular differentiation
and embryonic stem cell development as well as tumor progres-
sion. In light of this, we postulated whether differences in miRNA
expressionmight distinguish CD133+ TICs from their more differ-
entiated progeny. We profiled isolated CD133+ TICs and
CD133 cells from freshly resected tumors from HCC patients
(n = 5) and HCC cell lines (n = 2; Huh7 and PLC8024) using
a SYBR Green-based qPCR miRNA array containing 95 well-
characterized human miRNAs known to be involved specifically
in stem cell self renewal and differentiation. miRNAs that
displayed >2-fold changes in HCC patients and cell lines were
tabulated. Altogether, 5 upregulated and 24 downregulated
miRNAs were found among the clinical HCC specimens. In
parallel, four reproducibly upregulated and nine downregulated
miRNAs were identified across all HCC cell lines. We reasoned
that relevant miRNAs should commonly appear in both primary
tumors and HCC cell lines. Therefore, we combined the two
different data sets in a Venn diagram and observed a total of
eight expression-altered miRNAs common to all cells: two upre-
gulated (miR-130b and miR-369-5p) and six downregulated (let-
7a, miR-30c, miR-33, miR-153, miR-1, andmiR-10b) (Figure 3A).
To validate our profiling findings, we performed a second round
of qPCR using the more precise TaqMan primers on selected
commonly deregulated miRNAs sorted by CD133 from HCC
cells PLC8024 and Huh7, as well as a on a series of liver cell lines
with differing CD133 expression levels (data not shown). Prefer-
ential deregulation of the miRNAs was indeed verified, whereas,698 Cell Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier Incin parallel assays, two control miRNAs (miR-24 andmiR-92) were
found to be unchanged in expression (data not shown).
However, only the expression of miR-130b could be closely
correlated with CD133 expression in the examined series of liver
cell lines (Figure 3B). Liver cell lines with low CD133 expression
had relatively lower levels of miR-130b (HepG2, H2P, H2M),
while, in contrast, liver cell lines with high CD133 levels
expressed relatively higher levels of miR-130b (PLC8024,
Huh7, Hep3B) (Figures 3B and S1). In view of this, together
with the high fold-change difference in CD133+ TICs, we further
focused our studies on miR-130b.
miR-130b Is Preferentially Expressed in CD133+ TICs
Isolated from Freshly Resected HCCClinical Specimens
In addition to the five HCC clinical samples used in our initial
miRNA assay screening, we also tested the expression of
miR-130b in sorted CD133+ TICs and CD133 tumor cells from
15 additional freshly resected HCC patient specimens by
qPCR. In addition, miR-130b expression was also examined in
CD133+ TICs and CD133 tumor cells that were fractionated
by culture as spheroids. miR-130b expression was enriched in
the CD133+ subpopulation as compared with the CD133 coun-
terparts (n = 15, p = 0.018; Figure 3C). Furthermore, patient-
derived spheroids (Figure 3D; data representative of four
different tumors tested) that had enriched CD133 expression
also displayed enhanced miR-130b as compared with tumor
cells that were not CD133+ or their adherent, differentiated coun-
terparts, respectively. PLC8024 HCC spheres that received
a mixture of doxorubicin (0.25 mg/ml) and cisplatin (1.6 mg/ml)
chemotherapy, drugs commonly used in treating HCC patients
clinically, also showed increased miR-130b concomitant with
increased CD133 expression, as demonstrated by qPCR anal-
ysis (*, p < 0.05; Figure 3E).
miR-130b Exhibits an Increased Ability to Proliferate,
Self Renew, Form Tumors, and Resist Standard
Chemotherapy
We furthered our study to determine howmiR-130b regulates the
tumorigenicity, self renewal, and chemoresistance of CD133+
TICs. Stable transduction with a lentiviral vector containing the
primary transcripts of miR-130b produced high levels of mature
miR-130b in Huh7 CD133 or PLC8024 CD133- HCC cells (Fig-
ure S2). miR-130b-transduced CD133 HCC cells showed
enhanced proliferation compared with control cells transduced
with empty vector alone, as measured by XTT cell proliferation
assays (*, p = 0.01; Figure 4A). CD133 cells transduced with
miR-130b also expressed a higher level of stem cell-associated
genes, including b-catenin, Notch-1, Sox2, Nestin, Bmi-1, and
ATP-binding cassette half-transporterABCG2 (Figure 4B).More-
over, CD133 cells overexpressing miR-130b were also more
resistant to the chemotherapeutic drug doxorubicin (Figure 4C).
We then examined the effect of increased miR-130b expression
on self renewal and tumor growth. CD133 HCC cells with
lenti-miR-130b formed bigger and more spheres than CD133
cells carrying only the empty vector lentiviruses in a significantly
shorter period of time (Figure 4D). Importantly, miR-130b-trans-
duced spheroids could be passaged from one generation to
another, whereas the untransduced spheres could not be
passaged. When implanted into the flanks of SCID/Beige mice,.
Figure 3. miR-130b Is Preferentially Expressed in CD133+ TICs Isolated from Freshly Resected HCCClinical Specimens and CD133-Enriched
Spheroids
(A) Venn analyses of the up- and downregulatedmiRNAs in patient-derived HCC samples (left, blue shaded; n = 5 analyzed tumors) and in HCC cell lines PLC8024
and Huh7 (right, beige shaded) are shown. miRNAs that were significantly and commonly deregulated in both patients and cell lines are shown in the overlapping
area (pink shaded). Only those miRNAs whose expression levels displayed greater than 0.5-fold decreases or 2-fold increases were further studied. The table
shows a summary of the significantly differentially expressed miRNAs in CD133+ compared with CD133 HCC cells with fold change.
(B) CD133 (blue line) and miR-130b (red line) expression positively correlate across a panel of liver cell lines. See also Figure S1.
(C–E) A scatter dot plot shows the increased expression of miR-130b in CD133+ TICs as compared to CD133 counterparts in 15 HCC clinical specimens, as
detected by qPCR. qPCR analyses of miR-130b expression in (D) mechanically dissociated cancer spheroids (‘‘sphere’’) versus primary adherent HCC cells
(‘‘diff.’’), and in (E) PLC8024 HCC spheroids (‘‘sphere’’) versus their differentiated adherent counterpart (‘‘diff.’’) were performed following cisplatin (1.6 mg/ml)
and doxorubicin (0.25 mg/ml) treatment (*p < 0.05 compared with the differentiated counterpart). Differentiated adherent cells were defined as 1 (calibrator),
and the relative expression of miR-130b in the spheroids was expressed as the fold difference over this baseline. b-actin was used as an internal control.
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cantly enhanced (Figure 4E). Of the eight mice per group,
miR-130b-transduced CD133 HCC cells (miR-130b) gave rise
to tumors in four animals at approximately 9weeks postinjection,
while none of the animals injected with empty vector control
CD133HCC cells (EV) or CD133 cells alone could form tumors
(Table 1). Conversely, reducing miR-130b by lentiviral knock-
down in PLC8024 CD133+ TICs (ZIP miR-130b) yielded an
opposing effect, leading to a reduced ability to form tumors
in vivo as comparedwithCD133+ TICs transducedwith antisense
controls (ZIP CTRL) or CD133+ TICs alone (Table 1). Similarly,
miR-130b-expressing cells gave rise to more tumors when they
were serially passaged in vivo into secondary animal recipients
(data not shown) and in vitro as tertiary spheroids, suggesting
that miR-130b enhances self-renewing capacity (Figure 4F).
The tissue structure and cell morphology of tumors generated
from CD133+ TICs and CD133 cells expressing miR-130b
were not grossly different. Overall, CD133 cells stably express-
ing miR-130b displayed features more closely resemblingCelCD133+ TICs as compared with CD133- control cells.
Conversely, CD133+ cells with miR-130b stably repressed dis-
played features more closely resembling CD133 cells than
CD133+ TICs. The alteration of miR-130b by either lentiviral-en-
forced or reduced experiments did not alter CD133 expression
levels, suggesting that although miR-130b expression was
modulated by CD133, a reciprocal inflection was not observed
(Figure 4G).
TP53INP1 Is a Direct Target of miR-130b
In an effort to determine the potential downstreammRNA targets
regulated by miR-130b, we integrated mRNA expression
profiling findings with in silico predictions. Using the latter
prediction algorithms of PicTar and TargetScan, we found a total
of 289 downstream targets of miR-130b that were common in
both algorithms. Microarray analyses of mRNA expression in
HCCPLC8024 CD133 cells infected with miR-130b-expressing
or empty vectors yielded 271 downregulated genes with a fold
change of >2. Overall, with these data sets combined, threel Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier Inc. 699
Figure 4. The Role of miR-130b in Regulating Self Renewal, Proliferation, Tumorigenicity, and Chemoresistance in CD133+ TICs Is Shown
(A) Cell proliferation assay was performed for CD133- cells infected with miR-130b-expressing vector or EV (*p = 0.01 compared with CD133+ counterparts).
(B) qPCR analysis was performed for stem cell-associated genes in CD133 cells infected with miR-130b expressing vector (miR) or EV. CD133 cells carrying
the EV were defined as 1 (calibrator), and the relative expression of each gene was expressed as the fold difference over this baseline. b-actin was used as an
internal control.
(C) The percentages of viable cells from amongCD133+ or CD133 cells transducedwith miR-130b-expressing vector or EV following treatment of doxorubicin at
0 mg/ml (control) and 2 mg/ml were determined.
(D) CD133 cells expressing miR-130b generated a greater number of spheroids as compared with CD133 cells carrying the EV. The effect of miR-130b on
tumor formation in the SCID/Beige mouse xenograft model was determined.
(E) CD133+ or CD133 cells infected with miR-130b-expressing vector or EV were subcutaneously injected into the right posterior flank of each mouse. GFP
imaging was done for primary tumors formed by CD133 cells infected with miR-130b using the Xenogen system.
(F) (Left and middle) Serial passages of secondary- and tertiary-generation tumor cells harvested from transplanted mice were subjected to in vitro spheroid
formation assays. (Right) Histology panels represent H&E staining of xenografted tumors and confirm a HCC phenotype.
(G) qPCR analysis was performed for CD133 in Huh7 or PLC8024 CD133 cells infected with miR-130b (EV, miR-130b) or for CD133+ cells with antagonized
miR-130b (ZIP CTRL, ZIP miR-130b). See also Figure S2.
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TP53INP1 (tumor protein p53-inducible nuclear protein 1),
DPYSL2 (dihydropyrimidinase-related protein 2), and MDFIC
(MyoD family inhibitor domain-containing isoformp40) (Figure 5A
and Table S4). Among the three potential targets, we focused on
TP53INP1 because it is a known tumor suppressor gene and
because a recent report has demonstrated that TP53INP1 is
a functional target of miR-130b in cell-growth dysregulation of
human T cell lymphotrophic virus 1 (Yeung et al., 2008).
Base-pairing complementation found that the 30untranslated
region (UTR) of TP53INP1 encompasses two putative binding
regions (3927–3953 nt and 5525–5562 nt) bearing significant
complementarity against miR-130b (Figure 5B). These two
30UTR elements of TP53INP1 and miR-130b are extremely
conserved among different species, as shown by their identical700 Cell Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier Incsequences in mouse, rat, monkey, and human orthologs, sug-
gesting a functional role (Figure 5B). To validate whether
TP53INP1 is a bona fide target of miR-130b, a full-length human
TP53INP1 30UTR fragment, as well as two shorter fragments of
the TP53INP1 30UTR encompassing the potential binding
regions at positions 3927–3953 nt (site 1) and 5525–5562 nt
(site 2), were cloned downstream of the firefly luciferase reporter
gene. Compared with miR-control experiments, luciferase
activity wasmarkedly reduced by approximately 38% in the cells
cotransfected with miR-130b and the full-length TP53INP1
30UTR in the sense orientation. Cells cotransfected with miR-
130b and TP53INP1 30UTR site 1 and/or site 2 also showed
reduced luciferase activity by approximately 20%–29% as
compared to the miR-control. As a reflection of specificity, this
inhibitory effect was abolished when antisense TP53INP1.
Table 1. Engraftment Rates of CD133+ and CD133-
Subpopulations with or without miR-130b Expression
Cell Type
Tumor
Incidence Cell Number
Latency
(days)
CD133+ 7/8 10,000 45
6/8 5,000 51
CD133- 1/8 50,000 70
1/8 10,000 80
CD133EV1 2/8 10,000 76
0/8 5,000 -
CD133 miR-130b1 4/8 10,000 59
4/8 5,000 63
CD133+ ZIP CTRL2 6/8 10,000 49
5/8 5,000 55
CD133+ ZIP miR-130b2 2/8 10,000 68
1/8 5,000 82
1Overexpression of empty vector (EV) or miR-130b in CD133- cells.
2 Knockdown of empty vector (ZIP CTRL) or miR-130b (ZIP-miR-130b) in
CD133+ cells.
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sense constructs (Figure 5C). Interestingly, silencing TP53INP1
in PLC8024 CD133 cells did not augment CD133 or
miR-130b expression (Figure S3B). In contrast, silencing
CD133 in PLC8024 CD133+ (Figure S3A) or Huh7 CD133+
(data not shown) cells significantly repressed miR-130b expres-
sion by approximately 10- to 20-fold and concurrently upregu-
lated TP53INP1 expression, suggesting that miR-130b and
TP53INP1 are the direct downstream targets of CD133.
Interestingly, the expression of TP53INP1 was inversely corre-
lated with CD133 andmiR-130b, at both genomic and proteomic
levels, in a series of liver cell lines expressing different CD133
expression levels (Figures 5D, 5E, and S1). Abundant TP53INP1
expression was detected in CD133low HCC cells, like MiHA,
H2P and H2M. Conversely, CD133-expressing HCC cells like
HepG2, PLC8024, Huh7, and Hep3B expressed low levels, if
any at all, of TP53INP1. Likewise, the expression of TP53INP1
was also significantly repressed in CD133+ TICs isolated from
freshly resected HCC clinical specimens, as compared with the
CD133 HCC counterparts (n = 15, p = 0.043; Figures 5F
and 5H). Specifically, in the same 15 matched NT liver and HCC
clinical specimens we screened for miR-130b in Figure 3C,
a significant inverse correlation was detected between miR-
130b and TP53INP1 (p = 0.002, Pearson correlation = 0.732;
Figure 5G). The inverse correlation between miR-130b and
TP53INP1 in sorted CD133 subpopulations from clinical samples
and HCC cell lines was evident at both genomic and proteomic
levels (*, p < 0.01; Figures 5H and 5I). In addition, we also
observed an inverse TP53INP1 expression following lentiviral up-
regulation or downregulation of miR-130b expression in CD133
and CD133+ cells, respectively (Figures 5J and 5K).
TP53INP1Regulates Tumor Formation and Self Renewal
in CD133+ TICs
To further examine the role of TP53INP1 in HCC progression,
TP53INP1 protein was examined in 17 cases of matched NT
andHCC clinical specimens by immunoblot, as well as in a tissueCelmicroarray consisting of NT and HCC samples representative of
134 patients. TP53INP1 overexpression in NT was observed in
11 of the 17 (65%) matched cases examined by immunoblot
(Patients A, B, C, D, E, I, K, L, M, N and P; Figure 6A). Consis-
tently, the mean TP53INP1 expression in NT was significantly
elevated as compared with its corresponding adjacent HCC
tissue (n = 77 NT and HCC pairs, Paired t test, p < 0.001) (Fig-
ure 6B and Table S5). Intense cytoplasmic staining of TP53INP1
was observed in NT samples (Figure 6B; left), whereas signifi-
cantly lower expression was found in HCC samples (Figure 6B;
right). In addition, high TP53INP1 expression in HCC also corre-
lated with lower AFP levels (c2 test, p = 0.019) as well as smaller
tumor sizes (c2 test, p < 0.001) (Table S5). However, no signifi-
cant correlation was identified for TP53INP1 expression and
gender, age, presence of hepatitis B serum (HBS) antigen and
cirrhosis. To further our understanding of the functional role of
TP53INP1 in hepatocarcinogenesis, we generated stably
repressed TP53INP1 PLC8024 CD133- cells using a shRNA len-
tiviral knockdown system (Figure 6C). Of the five TP53INP1
shRNA clones, clones 464 and 4095 showed the most dramatic
TP53INP1 inhibition compared with nontarget control (NTC)
when examined by immunoblot and were thus chosen for further
studies (Figure 6C). Repressing TP53INP1 (clones 464 and 4095)
in PLC8024 CD133 cells had only a moderate effect on cell
proliferation (Figure 6D) but significantly enhanced the ability of
the cells to initiate spheroid formation when grown in nonadher-
ent serum-free conditions in vitro and to expand in subsequent
in vitro serial propagations (Figure 6E). More interestingly,
PLC8024 CD133 cells with repressed TP53INP1 demonstrated
an enhanced ability to initiate tumors when injected subcutane-
ously in immunodeficient animals compared with PLC8024
CD133 NTC cells (Figures 6F and 6H; n = 6 per group, cells
injected = 1 3 105). H&E staining of harvested xenografted
subcutaneous tumors confirmed a primary HCC phenotype (Fig-
ure 6G). Most importantly, primary xenografted tumors formed
by PLC8024 CD133 cells with repressed TP53INP1 (clones
464 and 4095) could also self renew, as demonstrated by their
ability to serially transplant in secondary mouse recipients. (Fig-
ure 6I; n = 5 per group, two groups of cells injected = 13 104 and
3 3 104). Serial transplantation of xenografted tumors in
secondary animal recipients demonstrated enhanced engraft-
ment ability, as demonstrated by the shorter period of time
needed for tumor initiation, as well as by the increase in the
number of tumors detected (Figure 6I).
To address whether the above-observed phenotype is indeed
due to the suppression of TP53INP1 and not from the targeting of
other cellular genes by miR-130b, a rescue experiment was per-
formed. We transduced CD133+ TICs with antagomirs to
miR-130b plus shRNA TP53INP1 or with the same antagomirs
plus scrambled shRNA controls. Indeed, CD133+ cells with
stably repressed miR-130b were enhanced in both spheroid
formation ability and self-renewal ability and showed increased
tumorigenicity in immunodeficient mice when shRNA TP53INP1,
but not the scrambled shRNA control, was cotransfected
(Figures 6J and 6K). Like CD133+ and CD133+ ZIP CTRL,
CD133+ cells stably repressed with miR-130b and transfected
with TP53INP1 could similarly initiate spheroid formation and
expand in subsequent serial propagations (Figure 6J). These
cells also displayed a similar ability to initiate tumors whenl Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier Inc. 701
Figure 5. TP53INP1 Is a Direct Target of miR-130b
(A) A Venn diagram displays candidate mRNAs that were computationally predicted to be targeted by miR-130b by PicTar (red), TargetScan (blue) and mRNA
expression profiling (green). See also Table S4.
(B) The mouse (mmu:Mus musculus), rat (rno: Rattus norvegicus), monkey (mml:Macaca mulatta), cow (btau: Bos taurus) and human (hsa: Homo sapiens) miR-
130b and the two predicted miR-130b binding sites in the 30UTR of TP53INP1 at nt 3927-3953 and nt 5525-5562 in different species were checked for alignment.
The positions of the miRNA binding sites corresponded to the location of the GenBank sequence NM_033285.
(C) An analysis of luciferase activity was performed. The full-length 30UTR of TP53INP1 (full-length) and two shorter fragments of TP53INP1 30UTR encompassing
the potential binding regions (site 1 at nt 3927-3953 and site 2 at nt 5525-5562) were PCR-amplified and then cloned downstream of a firefly luciferase gene. The
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miR-130b Regulates CD133+ Liver TICs via TP53INP1injected subcutaneously in immunodeficient animals as com-
pared to CD133+ and CD133+ ZIP CTRL cells (Figure 6K; n = 3
per group, mice sacrificed at 12 weeks). For better comparison,
experiments were carried out alongside CD133 and CD133+
ZIP miR-130b cells.
DISCUSSION
Epithelial tumors are made up of a heterogeneous population of
cells at multiple differentiation stages. This cellular heterogeneity
can be characterized by differences in the histopathologies, clin-
ical behaviors, molecular profiles, and functional properties.
Some studies suggest that such intratumoral heterogeneity
may arise from acquired mutations and epigenetic differences
of tumor cells through selective pressure during tumor evolution.
Recently, increasing evidence has lent support to the notion that
at the apex of this heterogeneous population of cells is a TIC
population that orchestrates aberrant differentiation, thereby re-
sulting in the observed cellular and functional heterogeneity of
epithelial tumors (Pardal et al., 2003). The origin of these cells
is unknown, but TICs may arise by mutations from normal
stem cells that retain self-renewal properties but acquire genetic
and/or epigenetic mutations, resulting in cancerous stem cells.
In contrast, TICs could also arise from mutated progenitors or
more committed differentiated cells that acquire the self-renewal
capacity and immortality typifying TICs.
Our current data show that HCC is driven by a small population
of TICs expressing the CD133 stem cell marker. Our data arewell
in line with the TIC hypothesis suggesting that tumors are gener-
ated and maintained by a small subset of cells with the ability to
self renew and differentiate into the bulk tumor population.
To date, the TIC hypothesis has been proven in a wide variety
of solid tumors, including breast, brain, colorectal, head and
neck, pancreatic, prostate, melanoma, and liver cancers (Vis-
vader and Lindeman, 2008). In addition, these results also
agree with our past studies where we identified a group of prim-
itive stem/progenitor cells from HCC cell lines and xenograft
tumors that is marked by a CD133 surface phenotype and bears
features including the ability to self renew, differentiate, and
initiate tumors in vivo and resist standard chemotherapy (Ma
et al., 2007, 2008). Likewise, using HCC cell lines, a few other
groups have also found liver TICs to be identified by the
CD133 surface phenotype (Suetsugu et al., 2006; Yin et al.,
2007; Zhu et al., 2010; Song et al., 2008). To our knowledge,specificity of the inhibition was determined using antisense constructs (30-50 orien
ization control for firefly luciferase activity. The inverse correlation of miR-130b a
(D) The inverse correlations of CD133 (blue line) and miR-130b (red line) against
lines. See also Figure S1.
(E) Immunoblots of the same series of HCC cell lines were performed for CD133 an
control.
(F) A scatter dot-plot showed decreased expression of TP53INP1 in CD133+ TIC
detected by qPCR.
(G-I) The inverse correlation betweenmiR-130b and TP53INP1 expression in CD1
with linear regression lines and Pearson correlation significance. TP53INP1 expre
lines was analyzed by both (H) immunoblot and (I) qPCR analysis. For qPCR, CD1
sion of TP53INP1 in CD133+ TICs was expressed as the fold difference over this
(J and K) qPCR (J) and immunoblots (K) were used to examine the expression of TP
CD133+ cells infected with ZIP miR-130b-expressing vector or ZIP control (CTRL
down and overexpression of miR-130b were detected, respectively. See also Fig
Celthis is the first study to identify CD133 as a marker of liver TICs
from freshly resected tumor specimens and, most importantly,
is one of the few studies to associate CD133 expression in
HCC with an advanced tumor stage, a larger tumor size, and
a poor prognosis.
CD133 is expressed by normal tissue-resident as well as
malignant stem cells of the hematopoietic, neural, pancreatic,
colonic, and endothelial lineages. CD133 is expressed on early
stem/progenitors but is usually no longer detectable upon
differentiation. Thus, our previous and present data from HCC
also correspond with these earlier findings where we identified
a subpopulation of CD133+ cells in a murine liver regenerating
model in which 70% of the liver was removed and a subpopula-
tion of CD133+ cells that bear self-renewal capacity because
they can be clonally expanded, are exclusively tumorigenic,
and can differentiate into CD133 cells (Ma et al., 2007). A couple
of recent studies in HCC have utilized CD90+CD44+ (Yang et al.,
2008) and EpCAM+ (Yamashita et al., 2009) for the identification
of TICs. Our preliminary data suggest that the expressions of Ep-
CAM and CD133 do overlap in some HCC tissue specimens and
cell lines but are not identical, while CD90 is undetectable in
these cells.
Following the identification of CD133 in liver TICs in the first
part of our study, the next step was to characterize the under-
lying molecular and biological mechanisms by which these cells
mediate tumor formation and growth. To date, the mechanisms
regulating these cells remain obscure. Thus, in the second part of
our study, we examined whether differences in miRNA expres-
sion could distinguish CD133+ HCC TICs from their more differ-
entiated progeny. Sorted CD133 subpopulations from HCC
clinical specimens and HCC cell lines were profiled for the
expression of 95 miRNAs. A significant overexpression of
miR-130b distinguishes CD133+ TICs from their differentiated
progeny. miR-130b was preferentially expressed in CD133+
spheres derived from HCC clinical samples as well as chemo-
therapy-treated unsorted spheres enriched for CD133. Func-
tional studies found that miR-130b was required for self renewal
in vitro, tumorigenicity in vivo, and chemoresistance. The over-
expression of miR-130b in CD133 cells enhanced proliferation,
displayed superior resistance to chemotherapeutic agents,
elevated the expression of stem cell-associated genes, and
gave enhanced tumorigenicity in vivo and greater potential for
self renewal in serial passages than when compared with control
cells transduced with empty vector alone. Conversely, thetation). The pRL-TK Renilla luciferase plasmid was cotransfected as a normal-
nd TP53INP1 expression in HCC clinical samples and cell lines is shown.
TP53INP1 (green line) expression were determined across a panel of liver cell
d TP53INP1 expression determinations. b-actin was used an as internal loading
s as compared to the CD133- counterparts in 15 HCC clinical specimens, as
33+ versus CD133- subpopulations in 15 HCC clinical samples was determined
ssion in CD133+ and CD133- cells from freshly resected tumors and HCC cell
33- cells of each sample were defined as 1 (calibrator), and the relative expres-
baseline level (*p < 0.01). b-actin was used as an internal control.
53INP1 in CD133- cells infected with miR-130b-expressing vector or EV and in
). Increased and suppressed expressions of endogenous TP53INP1 by knock-
ure S3.
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Figure 6. TP53INP1 Regulates Tumor Formation and Self Renewal in CD133+ TICs
(A) TP53INP1 expression was determined in 17 cases of matched NT and HCC (Patients A to Q) by immunoblot. b-actin was used an as internal loading control.
(B) IHC staining for TP53INP1 expression was performed in a tissuemicroarray consisting of NT and HCC samples representative of 134 patients. Representative
images of TP53INP1 overexpression in NT compared to the matched HCC counterparts are shown. Intense cytoplasmic staining of TP53INP1 was observed in
NT (left), whereas HCC showed little or no staining (right). IHC images were taken at a 2003 magnification. See also Table S5.
(C) Immunoblot analysis for TP53INP1 expression in PLC8024 CD133- cells following shRNA TP53INP1 stable knockdown determined that clones 464 and 4095
significantly repress TP53INP1 expression compared with NTC. b-actin was used an as internal loading control.
(D) The knockdown of TP53INP1 in PLC8024 CD133 cells (clones 464 and 4095) resulted in moderate augmentation in cell proliferation compared with NTC.
(E) PLC8024 CD133 cells with repressed TP53INP1 (clones 464 and 4095) generated a greater number of spheroids (top) and could be serially passaged
(bottom) as compared with NTCs.
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site effect.
By integrated analyses through mRNA expression profiling
and in silico predictions, we identified TP53INP1 as a functional
downstream target of miR-130b. Five lines of evidence support
this finding. First, there are two highly conserved miR-130b
binding sites in the 30UTR of TP53INP1. Second, the stable over-
expression or knockdown of miR-130b reduced or enhanced
TP53INP1 levels, respectively, at both the mRNA and protein
levels, in a number of HCC cell lines. Third, expression of
miR-130b and TP53INP1 were found to be significantly inversely
correlated in HCC clinical specimens. Fourth, TP53INP1 30UTR-
mediated luciferase activity is specifically responsive to trans-
ducedmiR-130b. Fifth, a rescue experiment where CD133+ cells
that stably repressed miR-130b with overexpressed TP53INP1
expression and dually transfected with shRNA TP53INP1,
successfully enhanced the cells’ ability to grow and self renew.
TP53INP1 is a proapoptotic stress-induced p53 target gene. It
is a tumor suppressor gene with a known role in cellular homeo-
stasis through its antiproliferative and proapoptotic activities via
both p53-dependent and p53-independent means (Tomasini
et al., 2001; Tomasini et al., 2002; Okamura et al., 2001). It is
an alternatively spliced gene encoding two protein isoforms
(TP53INP1a and TP53INP1b), and when overexpressed, both
isoforms exert a tumor suppressor function, mainly by inducing
the transcription of target genes involved in cell-cycle arrest
and p53-mediated apoptosis as part of the cell response to gen-
otoxic stress. Findings in recent years have shown a significant
reduction or loss of TP53INP1 expression during the develop-
ment of cancers of the stomach (Jiang et al., 2006), breast
(Ito et al., 2006), and pancreas (Gironella et al., 2007). Mice defi-
cient for TP53INP1 also present with exacerbated colitis-associ-
ated carcinogenesis (Gommeaux et al., 2007). In addition,
TP53INP1 expression was lost in rat preneoplastic lesions in
the liver (Ogawa et al., 2005). Recently, miR-130b was found to
work as a tumor suppressor by silencing TP53INP1 in human
T cell leukemia (Yeung et al., 2008). Our data in the last part of
this paper found that miR-130b-induced downregulation of
TP53INP1 promotes tumor growth and self renewal in CD133+
TICs. TP53INP1 expression determinations on a tissue microar-
ray consisting of NT and HCC specimens and by immunoblot
found that TP53INP1 was significantly downregulated in HCC
as compared with NT tissue. Silencing TP53INP1 in PLC8024
CD133 cells enhanced both spheroid formation and tumorige-
nicity in immunodeficient mice as well as self renewal as evident
by serial transplantation. Further, a rescue experiment found
CD133+ TICs transduced with antagomirs to miR-130b plus
shRNA TP53INP1, but not scrambled shRNA control, enhanced
ability of the cells to form spheres, to develop tumors in immuno-
deficient mice, as well as to self-renew. miR-130b thus acts as(F) Representative images are shown for the tumors (black arrow, subcutaneou
shRNA TP53INP1 clones 464 and 4095 or NTC when injected subcutaneously in
(G) Histology panels representing H&E staining of harvested tumors confirmed a
(H) Tumor volumes were measured after tumor cell inoculation every 10 days for
(I-K) Serial transplantation of xenografted TP53INP1 clone 4095 tumors in secon
ability, as demonstrated by the shorter period of time needed for tumor initiation a
number of mice injected is shown above the bars. The suppression of TP53INP1
ability to form spheroids in primary (white column), secondary (gray column) and t
nodeficient mice (n = 3 per group). Black arrows depict larger tumors, and white
Cela regulator of stemness and tumorigenicity by silencing
TP53INP1.
Clinically, the relevance of TICs has become more evident,
underscoring the importance of this theory and the need for
the better characterization of these cells. The characterization
of molecular targets downstream of CD133+ liver TICs in this
study not only will allow for better understanding of the mecha-
nisms regulating this specific population of cells but also will
provide insight into the gradual improvement of more effective
cancer therapies against this disease.
EXPERIMENTAL PROCEDURES
Fresh Clinical Tissue Specimens
Fresh human liver tumor and adjacent NT tissue specimens were obtained in
accordance with the ethical standards of the institutional committee on
human experimentation from 83 patients undergoing hepatectomy for HCC.
Specimens were collected between 2008 and 2009 at the Queen Mary
Hospital or the Prince of Wales Hospital in Hong Kong. No previous local or
systemic treatment had been conducted for these patients prior to operation.
Histological examination was carried out by pathologists, and diagnosis was
made based on the microscopic features of the carcinoma cells. Tumors were
graded using the American Joint Committee on Cancer (AJCC)/International
Union Against Cancer (UICC) tumor staging system. Surgical specimens
were obtained at the time of resection from all patients. All samples were
received in the laboratory within 20 min, immediately mechanically disaggre-
gated and digested with type IV collagenase (Sigma-Aldrich; Louis, MO), and
then resuspended in DMEM/F12 medium containing penicillin (500 U/ml) and
streptomycin (500 mg/ml). Single-cell suspensions were obtained by filtration
through a 100 mm filter (BD Biosciences; Franklin Lakes, NJ). Dead cells and
red blood cells were removed using the Ficoll gradient centrifugation method.
Remaining red blood cells were lysed with ACK buffer (Invitrogen; Carlsbad,
CA). The number of viable cells was counted and analyzed using trypan blue
staining.
Clinical Samples for CD133 Survival Correlation Studies
Liver tumor tissue specimens were obtained from 41 patients who underwent
liver resection for HCC between 2000 and 2005 at the Queen Mary Hospital in
Hong Kong. The patients included 37 men and 4 women with ages ranging
from 28 to 80 years (median: 55 years). Tumors were graded using the
AJCC/UICC tumor staging system. The clinical information of the patients is
summarized in Table S1. Informed consent was obtained from all patients
before the collection of liver specimens, and the study was approved by the
Ethics Committee of the University of Hong Kong.
Cell Sorting and Flow Cytometry
Cell sorting by flow cytometry was performed on liver cells using PE-conju-
gated monoclonal mouse anti-human CD133/1 (AC133, Miltenyi Biotec;
Auburn, CA). Isotype control mouse IgG1k-PE (eBioscience; San Diego, CA)
served as a control. Samples were analyzed and sorted on a BD FACSVantage
SE (BD Biosciences). Only the top 25% most brightly stained or the bottom
20% most dimly stained cells were selected as positive and negative popula-
tions, respectively. Magnetic cell separation was performed on tumor cell pop-
ulations obtained from enzymatic dissociation of HCC specimens using mi-
crobeads conjugated with CD133/1 (AC133, Cell Isolation Kit, Miltenyi
Biotec). Magnetic separation was performed twice. The quality of sortings tumor) formed in SCID/Beige mice by PLC8024 CD133 cells infected with
the right posterior flank (n = 6 per group).
primary HCC phenotype.
a period of 15 weeks.
dary animal recipients (n = 5 per group) demonstrated enhanced engraftment
nd the increased number of tumors detected. The number of tumors detected/
in CD133+ TICs with stably repressed miR-130b resulted in a rescue of (J) its
ertiary passages (blue column) as well as (K) its ability to form tumors in immu-
arrows depict smaller tumors.
l Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier Inc. 705
Cell Stem Cell
miR-130b Regulates CD133+ Liver TICs via TP53INP1was controlled by flow cytometry with an antibody against a different CD133
epitope (CD133/2, AC141, Miltenyi Biotec). Viability was assessed using try-
pan blue exclusion. Sorted and unsorted cells from human specimens and
xenografts were analyzed for CD133 expression using PE-conjugated
CD133/1 (AC133, Miltenyi Biotec) and isotype control mouse IgG1k-PE (eBio-
science). CD133+ sorted cells were analyzed for panendothelial CD31 and
panleukocyte CD45 expression using FITC-conjugated monoclonal mouse
anti-human CD31 (eBioscience) and FITC-conjugated monoclonal mouse
anti-human CD45 (clone 2D1, Stem Cell Technologies) or isotype control
mouse IgG1k-FITC (eBioscience). Flow cytometry was performed on a FACS-
Calibur apparatus, and data were analyzed using CellQuest software (BD
Biosciences).
miRNA Profiling
miRNA expression profiling was performed using total RNA with the Stem
Cell miRNA qPCR Array (System Biosciences; Mountain View, CA), which
simultaneously profiles 95 different human miRNAs with potential roles in
cellular self renewal and differentiation. Human small nuclear U6 RNA was
amplified as a normalization control. All miRNAs were registered with the
Sanger miRBase database. qPCR was performed using SYBR Green as
mentioned above. The analysis was performed using software provided by
System Biosciences.
Animal Model and Animal Charge-Couple Device Experiments
The study protocol was approved by and performed in accordance with the
Committee of the Use of Live Animals in Teaching and Research at the Univer-
sity of Hong Kong. Tumorigenicity was determined by orthotopic injection into
the liver or subcutaneous injection into the flank of 4-to-5-week old SCID/Beige
mice. For orthotopic injections, single dissociated cells from freshly resected
tumors were sorted for CD133+ and CD133 cells and were injected orthotopi-
cally into the liver in a mixture of complete medium and Matrigel (BD Biosci-
ences) at a 1:1 ratio. For miR-130b transplantation studies, CD133+ TICs
infected with antagomirs to miR-130b or antisense control or CD133 cells in-
fected with miR-130b or empty vector were injected subcutaneously in
complete medium. Each group contained eight animals. After tumors were de-
tected, tumor sizes were measured every 3 days by calipers, and tumor
volumes were calculated as volume (cm3) = L 3W2 3 0.5. Harvested tumors
were imaged immediately after sacrifice. Briefly, imaging was done using
a Xenogen IVIS 100 cooled charge-coupled device camera (Caliper Life
Sciences; Hopkinton, MA). The acquisition time ranged from 30 s to 1 min. A
gray-scale reference imagewasobtained, followedby theacquisitionof abiolu-
minescent image. The images shown are pseudoimages of the emitted light in
photons/s/cm2/steradian superimposed over the gray-scale photographs of
the animal. For TP53INP1 transplantation studies, lentiviral-delivered shRNA
TP53INP1 or shRNA nontarget control CD133 cells were injected subcutane-
ously in complete medium. Each group contained five or six animals. Cryosec-
tions (5 mm thick) were stained with H&E and used for IHC. Animals that were
injected with tumor cells but showed no sign of tumor burden were generally
terminated 5 months after tumor cell inoculation, and animals were opened
up at the injection sites to confirm that there was no tumor development.
Statistical Analysis
All statistical analyses were performed using PASW Statistics 18.0 (SPSS, Inc.;
Chicago, IL), with the exception of the significance in bar graphs, in which
case analyses were performed by applying the independent t test using Micro-
soft Office Excel software (Microsoft Corp.; Redmond, WA). A p value of less
than 0.05 was considered significant. Differences in CD133 expression among
different clinicopathological stageswereanalyzedbyChi-square (c2) test.Cases
with DCt values falling within the range of half standard deviation (SD) plus or
minus the mean value (10.36 ± 1.6) were excluded from the analysis. Cases
withDCt lower than themeanvalueminushalf of theSDwereclassifiedashaving
high CD133 expression, while cases with DCt higher than the mean value plus
half of theSDwereclassifiedashaving lowCD133expression.TheKaplan-Meier
method and the log-rank test were used to compare the survival, defined as the
time fromsurgeryuntil death (livingpatientswerecensoredat the timeof their last
follow up), of patients with CD133+ and patients with CD133 primary tumors.
For the calculation of differences in themeanscore of TP53INP1 in theNTversus
HCC tissuemicroarrays, only 77 of the 134 patients were included in the paired t706 Cell Stem Cell 7, 694–707, December 3, 2010 ª2010 Elsevier Inctest calculation. The remaining 57 patients were negative for TP53INP1 in either
NT or T and thus had to be excluded.
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